Brad Partridge

Bio: Brad Partridge is an academic researcher from University of Queensland. The author has contributed to research in topics: Life expectancy & Neuroenhancement. The author has an hindex of 17, co-authored 39 publications receiving 740 citations. Previous affiliations of Brad Partridge include Royal Brisbane and Women's Hospital & Mayo Clinic.

Addiction: Current Criticism of the Brain Disease Paradigm

Abstract: To deepen understanding of efforts to consider addiction a “brain disease,” we review critical appraisals of the disease model in conjunction with responses from in-depth semistructured stakeholder interviews with (1) patients in treatment for addiction and (2) addiction scientists. Sixty-three patients (from five alcohol and/or nicotine treatment centers in the Midwest) and 20 addiction scientists (representing genetic, molecular, behavioral, and epidemiologic research) were asked to describe their understanding of addiction, including whether they considered addiction to be a disease. To examine the NIDA brain disease paradigm, our approach includes a review of current criticism from the literature, enhanced by the voices of key stakeholders. Many argue that framing addiction as a disease will enhance therapeutic outcomes and allay moral stigma. We conclude that it is not necessary, and may be harmful, to frame addiction as a disease.

Deflating the Neuroenhancement Bubble

Abstract: This article questions the evidence base for some commonly accepted assumptions among bioethicists about the prevalence of neuroenhancement among college students and the degree to which putative neuroenhancers in fact enhance cognitive functioning. We argue that the evidence on the prevalence of stimulant drug use does not support bioethicists’ claims that neuroenhancement use of these drugs is widespread; that the evidence that putatively enhancing pharmaceuticals are truly neuroenhancing is much weaker than often supposed; that bioethicists have underestimated the challenges in assessing the safety and efficacy of putative neuroenhancers; and that the assumption that neuroenhancement is a novel development has deflected attention from historical experiences with other putatively enhancing pharmaceutical drugs such as cocaine and the amphetamines.

Australian university students' attitudes towards the use of prescription stimulants as cognitive enhancers: perceived patterns of use, efficacy and safety

Abstract: Introduction and Aims Recent, high profile articles in leading science journals have claimed that the enhancement use of prescription stimulants is a common practice among students worldwide. This study provides empirical data on Australian university students' perceptions of: (i) the prevalence of prescription stimulant use by their peers for cognitive enhancement; (ii) motivations for such use; (iii) efficacy; and (iv) its safety. Design and Methods Participants were 19 Australian university students with an average age of 24 who were recruited through emails lists, notice board posters and snowball sampling. Semi-structured interviews were conducted during 2010 and 2011, recordings transcribed and responses coded using thematic analysis. Results Participants typically did not believe the use of stimulants for cognitive enhancement was common in Australia. Perceived motivations for use included: (i) getting ahead' to perform at high levels; (ii) keeping up' as a method of coping; and (iii) going out' so that an active social life could be maintained in the face of study demands. Australian students were generally sceptical about the potential benefits of stimulants for cognitive enhancement and they identified psychological dependence as a potential negative consequence. Discussion and Conclusions This study is an important first step in understanding the use of stimulants for cognitive enhancement in Australia, amid calls for more widespread use of cognitive enhancing drugs. It is important to conduct further studies of the extent of cognitive enhancement in Australia if we are to develop appropriate policy responses. [Partridge B, Bell S, Lucke J, Hall W. Australian university students' attitudes towards the use of prescription stimulants as cognitive enhancers: Perceived patterns of use, efficacy and safety. Drug Alcohol Rev 2013;32:295-302]

Australian University Students’ Attitudes Towards the Acceptability and Regulation of Pharmaceuticals to Improve Academic Performance

Abstract: There is currently little empirical information about attitudes towards cognitive enhancement - the use of pharmaceutical drugs to enhance normal brain functioning. It is claimed this behaviour most commonly occurs in students to aid studying. We undertook a qualitative assessment of attitudes towards cognitive enhancement by conducting 19 semi-structured interviews with Australian university students. Most students considered cognitive enhancement to be unacceptable, in part because they believed it to be unethical but there was a lack of consensus on whether it was similar or different to steroid use in sport. There was support for awareness campaigns and monitoring of cognitive enhancement use of pharmaceutical drugs. An understanding of student attitudes towards cognitive enhancement is important in formulating future policy.

Australian University Students' Coping Strategies and Use of Pharmaceutical Stimulants as Cognitive Enhancers.

Abstract: Background: There are reports that some university students are using prescription stimulants for non-medical ‘pharmaceutical cognitive enhancement (PCE)’ to improve alertness, focus, memory, and mood in an attempt to manage the demands of study at university. Purported demand for PCEs in academic contexts have been based on incomplete understandings of student motivations, and often based on untested assumptions about the context within which stimulants are used. They may represent attempts to cope with biopsychosocial stressors in university life by offsetting students’ inadequate coping responses, which in turn may affect their cognitive performance. This study aimed to identify (a) what strategies students adopted to cope with the stress of university life and, (b) to assess whether students who have used stimulants for PCE exhibit particular stress or coping patterns. Methods: We interviewed 38 university students (with and without PCE experience) about their experience of managing student life, specifically their educational values, study habits and achievement, stress management, getting assistance, competing activities and responsibilities, health habits, and cognitive enhancement practices. All interview transcripts were coded into themes and analysed. Results: Our thematic analysis revealed that, generally, self-rated coping ability decreased as students’ self-rated stress level increased. Students used emotion- and problem-focused coping for the most part and adjustment-focused coping to a lesser extent. Avoidance, an emotion-focused coping strategy, was the most common, followed by problem-focused coping strategies, the use of cognition on enhancing substances, and planning and monitoring of workload. PCE users predominantly used avoidant emotion-focused coping strategies until they no longer mitigated the distress of approaching deadlines resulting in the use of prescription stimulants as a substance-based problem-focused coping strategy. Conclusion: Our study suggests that students who choose coping responses that do not moderate stress, where possible, may cause themselves additional distress and avoid learning more effective coping responses. Helping students to understand stress and coping, and develop realistic stress appraisal techniques, may assist students in general to maintain manageable distress levels and functioning. Furthermore, assisting students who may be inclined to use prescription stimulants for cognitive enhancement may reduce possible drug-related harms.

Prevalence of attention-deficit/ Hyperactivity disorder: A systematic review and meta-analysis

Abstract: BACKGROUND AND OBJECTIVE: Overdiagnosis and underdiagnosis of attention-deficit/hyperactivity disorder (ADHD) are widely debated, fueled by variations in prevalence estimates across countries, time, and broadening diagnostic criteria. We conducted a meta-analysis to: establish a benchmark pooled prevalence for ADHD; examine whether estimates have increased with publication of different editions of the Diagnostic and Statistical Manual of Mental Disorders (DSM); and explore the effect of study features on prevalence. METHODS: Medline, PsycINFO, CINAHL, Embase, and Web of Science were searched for studies with point prevalence estimates of ADHD. We included studies of children that used the diagnostic criteria from DSM-III, DSM-III-R and DSM-IV in any language. Data were extracted on sampling procedure, sample characteristics, assessors, measures, and whether full or partial criteria were met. RESULTS: The 175 eligible studies included 179 ADHD prevalence estimates with an overall pooled estimate of 7.2% (95% confidence interval: 6.7 to 7.8), and no statistically significant difference between DSM editions. In multivariable analyses, prevalence estimates for ADHD were lower when using the revised third edition of the DSM compared with the fourth edition (P = .03) and when studies were conducted in Europe compared with North America (P = .04). Few studies used population sampling with random selection. Most were from single towns or regions, thus limiting generalizability. CONCLUSIONS: Our review provides a benchmark prevalence estimate for ADHD. If population estimates of ADHD diagnoses exceed our estimate, then overdiagnosis may have occurred for some children. If fewer, then underdiagnosis may have occurred.

The Problem with NatureOur Posthuman Future: Consequences of the Biotechnology Revolution

Abstract: The dramatic advances in DNA technology over the last few years are the stuff of science fiction. It is now not only possible to clone human beings it is happening. For the first time since the creation of the earth four billion years ago, or the emergence of mankind 10 million years ago, people will be able to choose their children's' sex, height, colour, personality traits and intelligence. It will even be possible to create 'superhumans' by mixing human genes with those of other animals for extra strength or longevity. But is this desirable? What are the moral and political consequences? Will it mean anything to talk about 'human nature' any more? Is this the end of human beings? Post Human Society is a passionate analysis of the greatest political and moral problem ever to face the human race.

Enhancement as an American DilemmaBetter Than Well: American Medicine Meets the American Dream

Abstract: Americans have always been the world's most anxiously enthusiastic consumers of "enhancement technologies." Prozac, Viagra, and Botox injections are only the latest manifestations of a familiar pattern: enthusiastic adoption, public hand-wringing, an occasional congressional hearing, and calls for self-reliance. In a brilliant diagnosis of our reactions to self-improvement technologies, Carl Elliott asks questions that illuminate deep currents in the American character: Why do we feel uneasy about these drugs, procedures, and therapies even while we embrace them? Where do we draw the line between self and society? Why do we seek self-realization in ways so heavily influenced by cultural conformity?

Obesity and cognitive decline: role of inflammation and vascular changes.

Abstract: The incidence of obesity in middle age is increasing markedly, and in parallel the prevalence of metabolic disorders including cardiovascular disease and type II diabetes is also rising. Numerous studies have demonstrated that both obesity and metabolic disorders are associated with poorer cognitive performance, cognitive decline, and dementia. In this review we discuss the effects of obesity on cognitive performance, including both clinical and preclinical observations, and discuss some of the potential mechanisms involved, namely inflammation and vascular and metabolic alterations.